The CA125 antigen is a well-characterized serum marker for epithelial ovarian carcinoma and is utilized clinically to monitor response to therapy and recurrence of this malignancy. Recent identification and cloning of a cDNA molecule encoding the core peptide of the CA125 antigen revealed considerable homology to a family of membrane-associated mucins, and the CA125-encoding gene was designated MUC16. The cloning and characterization of MUC16 provides multiple new opportunities for a molecular genetic-based, mechanistic evaluation of the role of this molecule in ovarian neoplasia. The long-term goal of this project is to test the hypothesis that MUC16 plays a critical role in the development and/or maintenance of the malignant phenotype in ovarian carcinoma. This goal will be accomplished through a broad range of experimental approaches designed to gain insight into the function of MUC16 in normal development and cell biology, as well as in the neoplastic transformation of ovarian epithelial cells.
The specific aims of this project are to: 1) Annotate the genomic structures and analyze promoters of the MUC16 and Muc16 genes. Exon-intron boundaries, coding regions, untranslated regions and transcription factor binding sites will be characterized physically and functionally. 2) Characterize the function of Muc16 in vivo. Protein expression during embryonic development and in the neonatal and adult mouse and in murine ovarian cancers will be determined, as will the effects of transgenic knockdown of Muc16 in a temporal- and tissue-specific manner when crossed with transgenic mice prone to invasive ovarian carcinoma. 3) Using previously generate data on the regulation of MUC16 expression, correlate implied molecular pathways with promoter structure, and test the hypothesis that CA125 secretion results from post-translational processing of MUC16, exploring the mechanism of this processing. 4) Determine whether a reduction in MUC16 expression in human ovarian carcinoma cells affects the neoplastic phenotype. An RNA interference approach will be used to determine whether reduction of MUC16 mRNA levels in human ovarian carcinoma cells affects cell proliferation, differentiation, anchorage-independent growth or tumorigenicity in vivo. It is anticipated that studies of the function of MUC16 in multiple biological contexts will prove most effective in ultimately elucidating the role of this molecule in ovarian tumorigenesis.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA052477-14
Application #
7310997
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2006-05-01
Budget End
2007-04-30
Support Year
14
Fiscal Year
2006
Total Cost
$194,560
Indirect Cost
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Grisham, Rachel N; Sylvester, Brooke E; Won, Helen et al. (2015) Extreme Outlier Analysis Identifies Occult Mitogen-Activated Protein Kinase Pathway Mutations in Patients With Low-Grade Serous Ovarian Cancer. J Clin Oncol 33:4099-105
Rao, Thapi D; Tian, Huasong; Ma, Xun et al. (2015) Expression of the Carboxy-Terminal Portion of MUC16/CA125 Induces Transformation and Tumor Invasion. PLoS One 10:e0126633
Tew, William P; Colombo, Nicoletta; Ray-Coquard, Isabelle et al. (2014) Intravenous aflibercept in patients with platinum-resistant, advanced ovarian cancer: results of a randomized, double-blind, phase 2, parallel-arm study. Cancer 120:335-43
Tsuji, Takemasa; Sabbatini, Paul; Jungbluth, Achim A et al. (2013) Effect of Montanide and poly-ICLC adjuvant on human self/tumor antigen-specific CD4+ T cells in phase I overlapping long peptide vaccine trial. Cancer Immunol Res 1:340-50
Gardner, Ginger J; Baser, Raymond E; Brady, Mark F et al. (2012) CA125 regression in ovarian cancer patients treated with intravenous versus intraperitoneal platinum-based chemotherapy: a gynecologic oncology group study. Gynecol Oncol 124:216-20
Hyman, David M; Long, Kara C; Tanner, Edward J et al. (2012) Outcomes of primary surgical cytoreduction in patients with BRCA-associated high-grade serous ovarian carcinoma. Gynecol Oncol 126:224-8
Hyman, David M; Zhou, Qin; Iasonos, Alexia et al. (2012) Improved survival for BRCA2-associated serous ovarian cancer compared with both BRCA-negative and BRCA1-associated serous ovarian cancer. Cancer 118:3703-9
Marchini, Sergio; Poynor, Elizabeth; Barakat, Richard R et al. (2012) The zinc finger gene ZIC2 has features of an oncogene and its overexpression correlates strongly with the clinical course of epithelial ovarian cancer. Clin Cancer Res 18:4313-24
Iasonos, Alexia; Sabbatini, Paul; Spriggs, David R et al. (2012) Identifying clinical improvement in consolidation single-arm phase 2 trials in patients with ovarian cancer in second or greater clinical remission. Int J Gynecol Cancer 22:63-9
Soslow, Robert A; Han, Guangming; Park, Kay J et al. (2012) Morphologic patterns associated with BRCA1 and BRCA2 genotype in ovarian carcinoma. Mod Pathol 25:625-36

Showing the most recent 10 out of 109 publications